The Bridge Program has opened its doors for 2022 applications, as it provides 100 mid-career professionals tailored training on the scientific, legal, financial, clinical, regulatory and reimbursement disciplines that are essential to pharmaceutical commercialisation.
Using industry-led biotech and venture capital expertise, the programme empowers speakers and participants to share specific, detailed and practical translation know-how. Those involved will gain confidence and create networks and opportunities in all areas of the commercialisation pathway.
The programme is unique as it has been crafted and developed in collaboration with industry partners and with leaders in key global organisations in the biotech sector.
Applications are encouraged from mid-career professionals in the sector, including: entrepreneurs, researchers, scientists, legal practitioners (IP & patents), clinicians, venture capitalists, business development personnel, and staff from regulatory and government agencies. A background in pharma biotech, and demonstrated interest in a commercialisation career is essential.
Selection into the programme offers participants an exclusive opportunity to enter its annual video Pitch Competition, critiqued by industry partners. The winning pitches are awarded a US tour to visit the headquarters of major pharmaceutical companies to expand industry connections and discuss collaboration, travel permitting.
Biotech is a growing sector of high-value jobs, and skills and talent attraction will become a significant need for its future. The Bridge Program is one positive step in addressing this gap by upskilling our workforce, and enabling Australia to more effectively capitalise on its world-class medical research sector.
Launched in 2017, this programme has an alumni of over 700 and is fully supported by industry and government; there is no course fee. The Bridge Program is convened and administered by Queensland University of Technology, and match-funded through MTPConnect’s Project Fund Program and the Medical Research Future Fund’s Biomedical Translation Bridge Program.
The programme’s hybrid model offers online and in-person elements to increase accessibility across Australia.
Applications are open until 21 February 2022 via the online form .
